SELECTBIO - Antibodies in Drug Discovery Biographies

Home

Agenda

Keynote Speakers

Registration

Exhibition

Venue

Workshops

Co-Located Conferences

Social Program

Selection of Bispecific Abs Based on Fc Silencing/ The Role of Avidity to Select Therapeutic Bispecific Abs: EGFR x cMet

Tuesday, 7 March 2017 at 14:45

Add to Calendar ▼2017-03-07 14:45:002017-03-07 15:45:00Europe/LondonSelection of Bispecific Abs Based on Fc Silencing/ The Role of Avidity to Select Therapeutic Bispecific Abs: EGFR x cMetSELECTBIOenquiries@selectbiosciences.com

We show how receptor density levels of EGFR and cMet in different lung cancer cell lines can contribute to apparent synergy in targeting both receptors. This impacts the use of an appropriate selection strategy of bispecific Abs.

Mark Chiu, Principal Research Scientist, Janssen R&D Llc

Mark Chiu is leading the Biologics Engineering & Function group in Janssen Biotherapeutics. He has a Biophysics BA from University of California Berkeley, Biochemistry Ph.D. from University of Illinois – Urbana-Champaign. He has worked at Seton Hall University as a professor of chemistry and as a research investigator at Abbott Labs. While applying structure-function studies to optimize biotherapeutics, he actively pursues characterizations of marine and aquatic invertebrates.